Business Wire

5,736 of the World’s Poorest People Received the Gift of Sight in 2019 at the Tej Kohli Cornea Institute

Share

On the fourth anniversary of the Tej Kohli Cornea Institute in Hyderabad, the Tej Kohli Foundation has renewed its commitment of $14m of funding from 2020. During 2019 5,736 individuals were cured of blindness or severe visual impairment at The Tej Kohli Cornea Institute, which is a collaboration between the Tej Kohli Foundation in London, and the LV Prasad Eye Institute in Hyderabad, a World Health Organization Collaborating Centre.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005417/en/

The Tej Kohli Cornea Institute was inaugurated in December 2015 to tackle the problem of poverty blindness by providing free treatment to anyone who needs it. Since its inauguration the Cornea Institute has taken care of 223,404 outpatients, completed 43,255 surgical procedures, collected 38,225 donor corneas into its eye bank, utilized 22,176 donor corneas, trained 152 clinicians, published 202 papers and given 892 educational presentations.

Reaching people living with blindness and severe visual impairment in the hard-to-reach rural areas where 66% of Indians live is a particular challenge that the Tej Kohli Cornea Institute is uniquely solving. A unique presence of eye care centres in villages supplemented with a fully equipped mobile diagnostics van take eye care directly to hard-to-reach patients, with more than 100 corneal transplants completed so far in these rural areas.

Other 2019 operational highlights at the Tej Kohli Cornea Institute included:

  • 280,000 individuals called the ‘Call Netra’ toll free eye care helpline.
  • A special privilege ‘Keratoplasty card’ was issued to corneal transplant patients to ensure priority check-ups and access to care anytime and anywhere.
  • An education app was launched to continually assess cornea doctors in their evaluations.
  • The ECHO project linked expert specialist teams with clinicians in remote local communities.

According to the World Health Organisation, 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. 14m live in India, where between 6m and 7m people are currently waiting for a corneal transplant. At least 300,000 children in India have some form of severe visual impairment or blindness.

Whilst approximately 75% of corneal disease is curable, the costs of corneal transplantation surgery using donor cornea, and the many years of medicine needed to prevent rejection, makes treatment inaccessible to many. Born out of a partnership with the LV Prasad Eye Institute and the Tej Kohli Foundation, the Tej Kohli Cornea Institute is focussed on prevention, treatment and cure at no cost directly into these high-impact populations that are living needlessly with corneal blindness.

Dr Pravin K Vaddavalli, MD, Director of Tej Kohli Cornea Institute said:

“The last four years have been an opportunity to assess the magnitude of the problem of corneal blindness, create strategic partnerships to expand our reach and start to evolve ways and means to allow these patients to live longer, more productively and with dignity.”

Wendy Kohli, co-Founder of the Tej Kohli Foundation said:

“It’s an uncomfortable reality that millions of people worldwide are living with curable blindness that persists entirely because they cannot afford to access treatment. The impact of restoring a person’s vision on that person’s confidence, wellbeing and economic prospects is substantial. Through the Tej Kohli Cornea Institute we are able to make direct interventions into individual lives that help and transform entire families every single day.”

---

About The Tej Kohli Cornea Institute

The mission of the Tej Kohli Cornea Institute is to prevent, control and eliminate corneal blindness worldwide. The Institute is a global leader in research and development, preventative medicine, education and cornea transplants. The Institute enables access to affordable treatment through systemic long-term efforts to create widespread access to high-quality eye care facilities that are delivered by people with the resources, technical skills and compassion to handle diverse population segments.

http://www.tejkohlicorneainstitute.com

About LV Prasad Eye Institute

Established in 1987, the LV Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility. The Institute has ten active arms to its areas of operations: Clinical Services, Education, Research, Vision Rehabilitation, Rural and Community Eye Health, Eye Banking, Advocacy and Policy Planning, Capacity Building, Innovation and Product Development. LVPEI's mission is to provide equitable and quality eye care to all sections of society.

http://www.lvpei.org

About the Tej Kohli Foundation

Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness worldwide. Since 2015 the Foundation has funded the provision of corneal transplants in underserved communities in India through the Tej Kohli Cornea Institute; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness. In December 2019 the Foundation launched the ‘Future Bionics’ program to gift 3D printed bionic arms to children and young people who are living with limb difference in the United Kingdom.

http://www.tejkohlifoundation.com

END

Contact information

To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
tejkohlifoundation@buchanan.uk.com
+44 207 466 5000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GPD Companies, Inc. to Acquire Distrupol22.1.2021 16:33:00 EETPress release

GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0

Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 14:50:00 EETPress release

Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Dec. 31, 2020 Sept. 30, 2020 Dec. 31, 2019 Sequential Year-on-year Revenue $5,532 $5,258 $8,228 5% -33% Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4% Net income (loss) - GAAP basis $374 $(82) $333 n/m 12% Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33% Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bps Pretax segment operating income* $654 $575 $1,006 14% -35% Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bps Net income, excluding charges & credits* $309 $228 $545 35% -43% Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26% North America 1,167 1,034 2,339 13% -50% Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -

JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)22.1.2021 09:00:00 EETPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/ Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire) Development Background Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class res

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment22.1.2021 01:12:00 EETPress release

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine — dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV H

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)22.1.2021 00:30:00 EETPress release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde

Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 19:45:00 EETPress release

Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this

NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform21.1.2021 19:40:00 EETPress release

NumAlim announced an agreement with Dawex, the leader in Data Exchange technology, and Orange Business Services, a network-native digital services company, to deploy its agri-food digital exchange platform. By relying on these two leading players, NumAlim chose secure technological solutions guaranteeing the sovereignty of French food data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005722/en/ (Photo: Dawex) As early as Q1 2021, the NumAlim data and services exchange "Hub" will offer 18,000 companies in the food industry the opportunity to valorize, acquire and enrich all types of data: production, consumption, traceability, consumer opinions and research, as well as a wide range of services based on data (trend analysis, reformulation, regulatory watch…). "NumAlim is the answer to the needs for transparency, value creation and trust expressed by the food industry, consumers, and public authorities.” says Jérôme Fr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom